CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [**], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO BEAM THERAPEUTICS INC. IF PUBLICLY DISCLOSED. LICENSE AGREEMENTSubscription Agreement • July 29th, 2019 • Beam Therapeutics Inc. • Biological products, (no disgnostic substances) • Massachusetts
This License Agreement (this “Agreement”) is entered into as of this 27th day of June, 2017 (the “Effective Date”), by and between Beam Therapeutics, Inc., a corporation existing under the laws of the State of Delaware, having a place of business at c/o F-Prime Capital, 1 Main Street 13th Floor Cambridge, MA 02142 (“Licensee”), and President and Fellows of Harvard College, an educational and charitable corporation existing under the laws and the constitution of the Commonwealth of Massachusetts, having a place of business at Richard A. and Susan F. Smith Campus Center, Suite 727,1350 Massachusetts Avenue, Cambridge, Massachusetts 02138 (“Harvard”).
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [**], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO BEAM THERAPEUTICS INC. IF PUBLICLY DISCLOSED. LICENSE AGREEMENT by and between EDITAS...License Agreement • July 29th, 2019 • Beam Therapeutics Inc. • Biological products, (no disgnostic substances) • Massachusetts
This License Agreement (this “Agreement”), effective as of May 9, 2018 (the “Effective Date”), is made by and between Editas Medicine, Inc., a Delaware corporation (“Editas”), and Beam Therapeutics Inc., a Delaware corporation (“Beam”) (each, a “Party” and collectively, the “Parties”).
